Matching targeted therapies to gene mutations improves survival
Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared to those receiving non-matched, standard-of-care treatment, MD Anderson trial data revealed.
Long-term data from the center’s IMPACT trial, which compares treatments based on molecular profiling to standard-of-care treatments, showed the three-year, overall survival rate was 15 percent in...
Drug may benefit urinary tract cancer patients
In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held...
Could a pill replace chemotherapy for some patients?
In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...
PARP inhibitor shows benefit for small cell lung cancer patients
In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients — those whose tumors expressed SLFN11 — who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the...
Together, chemo and proton therapy lengthen survival for late-stage lung cancer patients
For patients with advanced, inoperable stage 3 lung cancer, chemotherapy and a specialized form of radiation treatment known as proton...
Two combination therapies shrink melanoma brain metastases in more than half of patients
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
Advanced radiation technique shows promise for lung cancer treatment
An advanced form of image-guided radiation therapy known as intensity modulated proton therapy (IMPT) has shown early promise for the treatment...
Chemotherapy may not be necessary for early-stage breast cancer
A new study from MD Anderson finds that women with early-stage breast cancer who had an intermediate risk recurrence score (RS)...
Hormone therapy shows big promise for ovarian cancer patients
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
Study links contralateral breast cancer with dense tissue
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the other breast, according...